CEO SUMMARY: In its first five years of offering clinical tests, Invitae has outspent revenue by $330.7 million. Yet its executives are confident that their company is on a path to becoming one of the dominant players in the genetic testing sector. This profile of Invitae will help pathologists and lab administrators understand more about […]
Invitae Investing Heavily To Expand Market Share
To become dominant, genetic testing company pushes aggressively to capture the market share
- By Robert Michel
- > From the Volume XXIV No. 12 - August 28, 2017 Issue
- Tags: cap, care contracts, clinical lab, clinical lab manager, clinical lab test, clinical lab tests, clinical laboratories, clinical tests, cost of gene sequencing, gene sequencing, genetic test, genetic testing, genetic testing companies, genetic testing lab, genetic testing labs, genetic testing services, genetic tests, invitae corp, invitae corporation, lab administrator, lab manager, lab managers, lab test, lab tests, laboratories, managed care, managed care contract, managed care contracts, Medicare, pathologists, Pathology group, pathology groups, test menu
